CN102293762B - Application of curcumin derivative in preparation of medicines for resisting diabetes and complication thereof - Google Patents
Application of curcumin derivative in preparation of medicines for resisting diabetes and complication thereof Download PDFInfo
- Publication number
- CN102293762B CN102293762B CN201010206369XA CN201010206369A CN102293762B CN 102293762 B CN102293762 B CN 102293762B CN 201010206369X A CN201010206369X A CN 201010206369XA CN 201010206369 A CN201010206369 A CN 201010206369A CN 102293762 B CN102293762 B CN 102293762B
- Authority
- CN
- China
- Prior art keywords
- diketone
- diene
- complication
- application
- heptan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 48
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical class C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title abstract 3
- 235000013305 food Nutrition 0.000 claims abstract description 13
- -1 3,5-di-tert-butyl-hydroxy phenyl Chemical group 0.000 claims description 19
- 229940109262 curcumin Drugs 0.000 claims description 19
- 235000012754 curcumin Nutrition 0.000 claims description 19
- 239000004148 curcumin Substances 0.000 claims description 19
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 19
- 230000002265 prevention Effects 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 10
- 235000013373 food additive Nutrition 0.000 claims description 9
- 239000002778 food additive Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000007500 overflow downdraw method Methods 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920003168 pharmaceutical polymer Polymers 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000005498 polishing Methods 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 18
- 239000008103 glucose Substances 0.000 abstract description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 7
- 230000037356 lipid metabolism Effects 0.000 abstract description 7
- 210000002376 aorta thoracic Anatomy 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 238000010172 mouse model Methods 0.000 abstract description 6
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 abstract description 4
- 230000007850 degeneration Effects 0.000 abstract description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract description 4
- 229960001052 streptozocin Drugs 0.000 abstract description 4
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract 1
- 108091005995 glycated hemoglobin Proteins 0.000 abstract 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000007170 pathology Effects 0.000 description 12
- 210000000709 aorta Anatomy 0.000 description 10
- 235000020828 fasting Nutrition 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 238000004043 dyeing Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241001597008 Nomeidae Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000013118 diabetic mouse model Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 231100000216 vascular lesion Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses application of a curcumin derivative to preparation of medicines for resisting diabetes and complication thereof and in particular relates to application of (1E,6E)-1,7-di(3,5-ditertbutyl-4-hydroxyl phenyl)heptyl-1,6-diene-3,5-diketone to preparation of medicines, health-care products and food for preventing and treating diabetes and complication thereof. The (1E,6E)-1,7-di(3,5-ditertbutyl-4-hydroxyl phenyl)heptyl-1,6-diene-3,5-diketone can obviously reduce serum, liver triglyceride, total cholesterol and low-density lipoprotein of high fat feed and streptozotocin induced diabetes model mice, can reduce fasting blood glucose and glycated hemoglobin of the model mice, can improve glucose tolerance of the model mice, can obviously improve glycometabolism and lipid metabolism of the diabetes model mice, and can obviously reduce fatty degeneration of liver and aortic arch and lesion of atherosclerosis.
Description
Technical field
The present invention relates to a kind of curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the 5-diketone is preparing prevention and treatment diabetes and the medicine of complication thereof, the application in the health product.
Background technology
Diabetes are to cause human dead the third-largest disease, and present global patient surpasses 200,000,000 people, and China patient nearly 2,000 ten thousand.In recent years, the sickness rate cumulative year after year of diabetes has a strong impact on people's life even threat to life, has brought heavy financial burden for society and individual, has become a more and more serious public health problem of countries in the world.
Diabetes cause time consuming hyperglycemia, cause sugar, fat, protein and insecondary vitamin, water, metabolic disturbance of electrolyte, Chang Bingfa atherosclerosis, microangiopathies, nervous system lesion etc., thus the infringement of a plurality of systems, a plurality of internal organs caused.Diabetes are in carcinogenesis of human, and the chronic complicating diseases sickness rate is up to 96.5%, and performance is complicated, is the main cause that causes diabetics to be disabled.Diabetic vascular complications comprises microvascular complication (diabetic nephropathy, Diabetic retinopathy) and macrovascular complications (atherosclerotic cardiovascular disease, coronary artery disease, cerebrovascular disease, peripheral blood vessel), wherein cardiovascular complication is the primary cause of the death of diabetics.As seen the metabolism disorder of diabetes with secondary, especially disorders of lipid metabolism, and vascular lesion is the main cause of diabetic complication, therefore effectively control blood glucose, improve lipid metabolism, suppress the generation that the generation of vascular lesion just might have the diabetes of preventing and treating and complication thereof.Studies have shown that in a large number high sugared state induces the free radical of generation to cause and unbalance between body oxidative stress and the anti-oxidative defense cause making progress of diabetes and related complication; Also exist between oxidative stress and the type ii diabetes insulin resistant to contact, hyperinsulinism also increases ROS, further causes insulin function impaired.Therefore use antioxidant to improve oxidative stress and may become the available strategy that reduces diabetic complication.
The synthetic antidiabetic drug untoward reaction of having gone on the market at present is serious, and price is more expensive.Acting on the chemicals that chronic complicating diseases of diabetes may target spot only has several (such as protein glycosylation inhibitor aminoguanidine, aldose reductase inhibitor fidarestats etc.), still is in during each clinical trial phase carries out, and also can not meet clinical needs far away.Motherland's medical science is having long history and significant curative effect aspect treatment diabetes and the complication thereof, seek effective ingredient or carry out on this basis structure of modification to obtain better medicine from Chinese herbal medicine, and DEVELOPMENT PROSPECT is very wide.
Curcumin is one of a few antioxidant that has simultaneously in a molecule phenolic hydroxyl group and two kinds of antioxidant groups of beta-diketon, and unique conjugated system of the enol-type structure of two phenolic hydroxyl groups and a beta-diketon makes its ability with significant Trapped free radical and ends the antioxidant activity of chain reaction.Studies have shown that in the external body that curcumin can remove ultra-oxygen anion free radical and hydroxyl radical free radical, suppress lipid peroxidation, increase the activity of polyphenoils such as SOD, GSH, GST, GPx etc.
(1E, 6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone (L3) is the derivant of curcumin, VENKATESAN etc. (J.Pharm.Pharmacol., 2000,52:1123-1128.) synthesized (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the 5-diketone, and find that this chemical compound has the activity that suppresses lipid peroxidation and remove free radical.Majeed etc. disclose the patent (U.S.Patent that this chemical compound is used for the treatment of cystic fibrosis, US 7,521,580), (1E still, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, whether the 5-diketone has the effect of the diabetes of preventing and treating and complication thereof, so far there are no bibliographical information.
Summary of the invention
The object of the present invention is to provide with curcumin derivate (1E, 6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the 5-diketone is raw material, for the preparation of alleviate, improve, prevent and treat type i diabetes, type ii diabetes or because of diabetes cause comprise hyperglycemia, impaired glucose tolerance, lipid metabolism is unusual and the medicine of the complication that above-mentioned illness causes.Described medicine comprises (1E, 6E)-1 of dose therapeutically effective, 7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone, and pharmaceutically acceptable carrier.
Another goal of the invention of the present invention is to provide a kind of (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in preparation prevention and treatment diabetes and complication medicine thereof; With (1E, 6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the 5-diketone is raw material, prepares to can be used for preventing or improve hyperglycemia, abnormal carbohydrate metabolism, diabetes or the purposes of health product, food or the food additive of the various clinical complications that cause because of diabetes.
Curcumin derivate of the present invention (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the structural formula of 5-diketone is as follows, hereinafter to be referred as L3.
The invention provides a kind of curcumin derivate (1E, 6E)-1 that contains dose therapeutically effective, 7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the medicine of the prevention of 5-diketone or treatment diabetes and complication thereof.
The invention provides a kind of curcumin derivate (1E, 6E)-1 that contains effective dose, 7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, health product or the food additive of the prevention of 5-diketone or treatment diabetes and complication thereof.
The invention provides a kind of curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in preparation prevention or treatment diabetes and complication medicine thereof.
The invention provides a kind of curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in health product, food or the food additive of preparation prevention or treatment diabetes and complication thereof.
Described curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in the medicine of preparation prevention or treatment diabetes and complication thereof is characterized in that: it is 1% to 100% (1E, 6E)-1 that described pharmaceutical pack contains mass percentage content, 7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the medicine of 5-diketone.Certainly contain mass percentage content and be 1% to 100% (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-I, 6-diene-3, the medicine of 5-diketone are the effective doses for the treatment of.
Described (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in health product, food or the food additive of preparation prevention or treatment diabetes and complication thereof is characterized in that: it is 1% to 99% (1E, 6E)-1 that described pharmaceutical pack contains mass percentage content, 7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the health product of 5-diketone or food or food additive.
Described medicine comprises pharmaceutically acceptable any dosage form that comprises in tablet, pill, capsule, granule, oral liquid, the injection that is selected from.
Described pharmaceutical pack contains pharmaceutically acceptable following any carrier or adjuvant, and described carrier or adjuvant comprise the various natural or synthetic pharmaceutical polymerses such as polyvinylpyrrolidone PVP, PLURONICS F87 (pluronic F68) and carbamide, organic acid, saccharide, alcohols, starch based and derivant thereof, cellulose family and derivant thereof, acrylic compounds, vinyl-based, ethylene oxide.
The medicine that described pharmaceutical dosage form can adopt the preparation method pharmaceutically of one of the following to make, described preparation method pharmaceutically comprises fusion method, solvent method, solvent-fusion method, polishing, spray drying method, hypobaric drying method, freeze-drying etc.
Principle of the present invention is based on (1E, 6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone (be called for short L3) can significantly reduce for a long time to feed with high lipid food and adds streptozotocin and induce the plasma triglyceride of diabetic mice, T-CHOL and low density lipoprotein, LDL, reduce fasting glucose and the glycolated hemoglobin of model mice, improve glucose tolerance in mice, obviously improve sugar, the lipid metabolism of diabetic mice, the steatosis of liver and aortic arch and atherosclerosis degeneration are obviously alleviated.
Beneficial effect of the present invention: the present invention has proved curcumin derivate (1E by zoopery, 6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the 5-diketone can alleviate, improve prevention and treatment type i diabetes, type ii diabetes or comprise hyperglycemia because of what diabetes caused, impaired glucose tolerance, the complication that the unusual and above-mentioned illness of lipid metabolism causes can be used for preparation prevention or improvement or treatment hyperglycemia, abnormal carbohydrate metabolism, the medicine of diabetes or the various clinical complications that cause because of diabetes, health product, food or food additive; Can significantly reduce blood plasma and liver tg, T-CHOL and low density lipoprotein, LDL that high lipid food adds the diabetic mice that streptozotocin induces, reduce model mice fasting glucose and glycolated hemoglobin, raising carbohydrate tolerance, obviously improve sugar, the lipid metabolism of diabetic mice, the steatosis of liver and aortic arch and Atherosclerosis pathological changes are obviously alleviated.And has preferably Expected Results.
Description of drawings
Fig. 1 is Normal group mouse liver pathology sheet figure of the present invention.
Fig. 2 is model group mouse liver pathology sheet figure of the present invention.
Fig. 3 is the 266mg/kg group mouse liver HE dyeing pathology sheet figure of L3 of the present invention.
Fig. 4 is the 532mg/kg group mouse liver HE dyeing pathology sheet figure of L3 of the present invention.
Fig. 5 is the 1064mg/kg group mouse liver HE dyeing pathology sheet figure of L3 of the present invention.
Fig. 6 is Normal group mouse aorta HE dyeing pathology sheet figure of the present invention.
Fig. 7 is model group mouse aorta HE dyeing pathology sheet figure of the present invention.
Fig. 8 is the 266mg/kg group mouse aorta HE dyeing pathology sheet figure of L3 of the present invention.
Fig. 9 is the 532mg/kg group mouse aorta HE dyeing pathology sheet figure of L3 of the present invention.
Figure 10 is the 1064mg/kg group mouse aorta HE dyeing pathology sheet figure of L3 of the present invention.
The specific embodiment
The present invention can further understand the present invention by specific embodiment given below and described accompanying drawing, but following embodiment is not limitation of the present invention.
Embodiment one:
Curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone (hereinafter to be referred as L3) is on the impact of hyperlipemia diabetic mice glycolipid metabolism
1.1 the foundation of hyperlipemia diabetic mice model
After all mice adaptabilities fed for 1 week, reserve at random 18 as Normal group, all the other modelings.Modeling all mice overnight fastings the previous day, streptozotocin is dissolved in to be made into weight percent concentration in the 0.1mol/L citric acid-sodium citrate buffer (pH 4.2) be 0.5% solution, model group and each treatment group are with 50mg/kg body weight lumbar injection, once totally 5 times every other day, the Normal group mouse peritoneal is injected isopyknic citric acid-sodium citrate buffer.In one week of interval after injecting 5 times, overnight fasting is cut tail blood sampling, and the rapid blood sugar instrument is surveyed fasting glucose, and with the dosage gavage glucose solution of 2g/kg body weight, cuts the tail blood sampling in 30,60,120 minutes after the gavage to survey carbohydrate tolerance, calculates area under the glucose tolerance curve.
1.2 the detection of pharmaceutical intervention and index
Carry out the stratified random grouping by area under the glucose tolerance curve, be divided into is 16 groups: Normal group (control, reserve), diabetic model group (model), L3 adopt respectively each 2 groups of 0.5mmol/kg (266mg/kg) dosage groups, 1mmol/kg (532mg/kg) dosage group, 2mmol/kg (1064mg/kg) dosage group, 9 every group of normal group, all the other every group 12.Begin gastric infusion after the grouping, once a day.Normal group and model group are given the excipient aqueous solution of equivalent every day.Normal group is raised with normal feedstuff, and all the other are respectively organized in grouping and begin to raise after the administration take high lipid food (by weight percentage prescription as: 10% Adeps Sus domestica, 2% cholesterol, 0.5% sodium cholate, 10% milk powder, 7.5% sucrose and 70% normal feedstuff powder).The experimental session animal freely drinks water, and quantitatively raises food by body weight.Monitoring body weight next day of mice.After 4 weeks of administration, put to death wherein 8 groups.After 16 weeks of administration, put to death all the other 8 groups.Survey blood glucose with glucose oxidase method, enzymic colorimetric is surveyed serum total cholesterol and serum triglycerides, use iodine [
125I] insulin radioimmunoassay, RIA medicine box plasma insulin level.
1.3 experimental result
1.3.1 on the glycometabolic impact of diabetic mice
As seen, after 4 weeks of L3 administration, area and glycolated hemoglobin all are significantly higher than Normal group under model group mice fasting glucose, the glucose tolerance curve from table 1, table 2, show that carbohydrate tolerance descends; Compare with model group, each dosage group mice fasting glucose of L3 all descends to some extent, and wherein high dose group significantly reduces; Administration group mice glycolated hemoglobin descends to some extent, and wherein middle dosage group and high dose group mice glycolated hemoglobin significantly reduce than model group; Compare with model group, administration group glucose tolerance in mice area under curve descends to some extent.16 weeks of L3 administration are similar to the situation in 4 weeks for the treatment of, and the fasting glucose of each dosage group of L3 and glycolated hemoglobin all obviously descend than model group, and plasma insulin level is also than the remarkable decline of model group.
Table 1L3 treated for 4 weeks to the impact of diabetic mice fasting glucose, carbohydrate tolerance and glycolated hemoglobin
*: P＜0.05vs Normal group; *: P＜0.01vs Normal group; #:P＜0.05vs model group; ##:P＜0.01vs model group, lower same.
Table 2L3 treated for 16 weeks to the impact of diabetic mice fasting glucose, glycolated hemoglobin and plasma insulin level
1.3.2 on the lipometabolic impact of diabetic mice
As seen from Table 3, administration 4 all model group mice plasma triglyceride (TG), T-CHOL (TC) and low density lipoprotein, LDL (LDL-C), high density lipoprotein (HDL-C) all are significantly higher than Normal group; Each administration group mice plasma TG all has remarkable reduction than model group; Dosage group and high dose group mice plasma TC all have remarkable reduction than model group among the L3; Dosage group and high dose group mice plasma LDL-C significantly reduce than model group among the L3.Each administration group HDL-C changes not obvious.After L3 treated for 16 weeks as seen from Table 4, the decline of each dosage group plasma TG of L3, TC, LDL-C was more obvious.
Table 3L3 treated for 4 weeks to the impact of diabetic mice blood fat
Table 4L3 treated for 16 weeks to the impact of diabetic mice blood fat
As seen, after 4 weeks of administration, 16 weeks, model group mouse liver TG, TC and LDL-C all are significantly higher than Normal group from table 5; Each administration group mouse liver TG all has remarkable reduction than model group; Dosage group and high dose group mouse liver TC all have remarkable reduction than model group among the L3; Dosage group and high dose group mouse liver LDL-C significantly reduce than model group among the L3.After L3 treated for 16 weeks as seen from Table 6, the decline of TG, TC, LDL-C was more obvious in each dosage group liver homogenate of L3.
Table 5L3 treated for 4 weeks to the impact of diabetic mice liver fat
Table 6L3 treated for 16 weeks to the impact of diabetic mice liver fat
Embodiment two
Curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone (L3) is on the impact of hyperlipemia diabetic mice vitals complication
2.1 the foundation of hyperlipemia diabetic mice model
With 1.1 methods.
2.2 the detection of pharmaceutical intervention and index
Animal grouping and administration together 1.1 methods.4 weeks of administration, 16 weeks are put to death respectively mice, separating mouse pancreas, liver, bilateral renal, heart and thoracic aorta, ventral aorta, and the cold saline rinsing, filter paper blots, and liver, two kidney are weighed, respectively the calculating body weight index.Thoracic aorta, ventral aorta are fixed take weight percent concentration as 4% paraformaldehyde solution, and liver and kidney weight percent concentration are that 10% neutral formalin solution is fixed.Liver, aorta are with paraffin embedding, section, and conventional H E dyes.
2.3 experimental result
2.3.1 the impact on Mouse Weight and liver/renal index
As seen from Table 4, after 4 weeks of administration, the Normal group weight of mice, the model group Mouse Weight significantly is lower than Normal group.Model group mice compared with normal matched group liver index significantly increases, and renal index is without significant change.Each administration group Mouse Weight, liver index and renal index than model group without significant change.
After treating for 4 weeks, table 7L3 respectively organizes Mouse Weight and liver/renal index
2.3.2 pathology of livers is observed
Perusal Normal group mouse liver profile is normal, kermesinus, and tunicle is smooth.The model group liver volume obviously increases, and peplos is nervous, and the edge is blunt thick, and the quality deliquescing has greasy feeling, and mattness is faint yellow.Each administration group liver outward appearance is between Normal group and model group.
Observed result is shown in Figure of description 1-5 under the light microscopic, Normal group murine liver tissue structural integrity, clear, and the lobules of liver structure is normal, and sinus hepaticus is high-visible, liver rope marshalling.The hepatocyte normal in size, karyon is placed in the middle, the abnormal changes such as fat-free degeneration (Figure of description 1).Model group lobules of liver boundary is unclear, the hepatic cords arrangement disorder, and most of sinus hepaticus disappears, and the hepatocyte volume obviously increases, even swelling is rounded, and cytoplasm contains a large amount of fat vacuoles not of uniform size, and karyon is pushed to periphery, exactly likes adipose cell.Endochylema is loose, is hydropic degeneration, and inflammatory cell infiltration (Figure of description 2) is arranged.
Hepatic cell fattydegeneration is respectively organized in administration all in various degree improve (Figure of description 3,4,5), and dose dependent is arranged, and drips minimizing the most obviously (Figure of description 5) with L3 high dose group fat.
2.3.3 changing, observes aorta pathology
The result is shown in Figure of description 6-10, and the aorta of Normal group mice comprises inner membrance, middle film and adventitia.Theca interna is thin, visible endotheliocyte and nucleus, and the endotheliocyte marshalling, inner membrance is smooth; Middle rete has plurality of resilient membranes, therebetween visible smooth muscle cell; Adventitia forms (Figure of description 6) by connective tissue.The apparition of model group aortic arch disease, the ductus arteriosus wall became uneven, inner membrance obviously thickens, and intimal surface is rough, endotheliocyte disappearance or discontinuous, SES broadening, it is common that fat stricture of vagina fat pinta becomes; The obvious irregular thickening of middle film, smooth muscle fiber significantly disorderly (Figure of description 7).Each administration group pathological change makes moderate progress (Figure of description 8,9,10), visible inner membrance limitation protuberance, and intimal thickening, middle film smooth muscle fiber is arranged slightly disorderly.High dose group and L3 high dose group are improved the most obviously (Figure of description 10).
Claims (7)
1. a curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in the medicine of preparation prevention or treatment diabetes and complication thereof.
2. a curcumin derivate (1E, 6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in health product, food or the food additive of preparation prevention or treatment diabetes and complication thereof.
3. curcumin derivate (1E as claimed in claim 1,6E)-1,7-two (3,5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in the medicine of preparation prevention or treatment diabetes and complication thereof is characterized in that: it is 1% to 100% (1E, 6E)-1 that described pharmaceutical pack contains mass percentage content, 7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone.
4. curcumin derivate (1E as claimed in claim 2,6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3, the application of 5-diketone in health product, food or the food additive of preparation prevention or treatment diabetes and complication thereof, it is characterized in that: it is 1% to 99% (1E that described health product, food or food additive include mass percentage content, 6E)-1,7-two (3, the 5-di-tert-butyl-hydroxy phenyl) heptan-1,6-diene-3,5-diketone.
5. such as claim 1 or 3 described application, it is characterized in that: the dosage form of described medicine is any dosage form that is selected from tablet, pill, capsule, granule, oral liquid, the injection.
6. such as claim 1 or 3 described application, it is characterized in that: the carrier of described medicine or adjuvant have at least a kind of for being selected from the natural or synthetic pharmaceutical polymers of polyvinylpyrrolidone PVP, PLURONICS F87 and starch based, cellulose family, acrylic compounds, vinyl-based, oxirane apoplexy due to endogenous wind.
7. application as claimed in claim 5 is characterized in that: described medicine adopts the preparation method of one of the following to make: fusion method, solvent method, solvent-fusion method, polishing, spray drying method, hypobaric drying method, freeze-drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010206369XA CN102293762B (en) | 2010-06-22 | 2010-06-22 | Application of curcumin derivative in preparation of medicines for resisting diabetes and complication thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010206369XA CN102293762B (en) | 2010-06-22 | 2010-06-22 | Application of curcumin derivative in preparation of medicines for resisting diabetes and complication thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102293762A CN102293762A (en) | 2011-12-28 |
| CN102293762B true CN102293762B (en) | 2013-03-20 |
Family
ID=45354600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010206369XA Expired - Fee Related CN102293762B (en) | 2010-06-22 | 2010-06-22 | Application of curcumin derivative in preparation of medicines for resisting diabetes and complication thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102293762B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019008002A1 (en) | 2017-07-03 | 2019-01-10 | Basf Se | Phenolic metal salts and their phenolic acids as polymer stabilizers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521580B1 (en) * | 2008-02-18 | 2009-04-21 | Sami Labs Ltd. | Non-cytotoxic synthetic analogues of (1E, 6E)-1, 7-Bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-Dione and therapeutic applications thereof in cystic fibrosis |
-
2010
- 2010-06-22 CN CN201010206369XA patent/CN102293762B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521580B1 (en) * | 2008-02-18 | 2009-04-21 | Sami Labs Ltd. | Non-cytotoxic synthetic analogues of (1E, 6E)-1, 7-Bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-Dione and therapeutic applications thereof in cystic fibrosis |
Non-Patent Citations (4)
| Title |
|---|
| P. VENKATESAN et al..Structure-Activity Relationships for the Inhibition of Lipid Peroxidation and the Scavenging of Free Radicals by Synthetic Symmetrical Curcumin Analogues.《J.Pharm.Pharmacol.》.2000,第52卷第1123-1128页. |
| Structure-Activity Relationships for the Inhibition of Lipid Peroxidation and the Scavenging of Free Radicals by Synthetic Symmetrical Curcumin Analogues;P. VENKATESAN et al.;《J.Pharm.Pharmacol.》;20001231;第52卷;第1123-1128页 * |
| 姜黄素对2型糖尿病大鼠血糖的影响;石磊;《河北医学》;20081031;第14卷(第10期);第1195-1197页 * |
| 石磊.姜黄素对2型糖尿病大鼠血糖的影响.《河北医学》.2008,第14卷(第10期),第1195-1197页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102293762A (en) | 2011-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN101181373B (en) | Cortex moutan valid target pharmaceutical combination, preparation method and application thereof | |
| CN101057678B (en) | Composition containing natural plant extraction or monomer | |
| CN105395563A (en) | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof | |
| CN102293762B (en) | Application of curcumin derivative in preparation of medicines for resisting diabetes and complication thereof | |
| CN1965873A (en) | Chinese medicinal extract having blood sugar-lowering activity, its preparation process, composition and use | |
| CN104739840A (en) | Novel use of asiatic acid in preparation of drugs for preventing and treating hyperlipidemia and fatty liver | |
| CN105920051B (en) | Flammulina velutipes extract and preparation method and application thereof | |
| CN103800352A (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN107115338A (en) | Application of the bicyclic alcohols in diabetes medicament is prepared | |
| CN101653499B (en) | New application of peony blood stasis removing preparation in preparing medicaments for preventing or treating diabetic complication | |
| CN106822338A (en) | Compound of reducing blood sugar and blood fat, prevention and/or treatment diabetes and its complication and application thereof | |
| CN101461802A (en) | Application of epi-gallocatechin-3-gallate in preparing medicament for preventing and treating high-fat fatty liver | |
| CN110638856A (en) | Medicine for preventing or reversing primary hypertension, type 2 diabetes or homologous diseases and animal model construction method | |
| CN104784192A (en) | Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide | |
| CN104547499A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and atherosclerosis | |
| CN102274514B (en) | Medicinal composition for preventing and treating type-II diabetes and complications thereof | |
| CN101584842B (en) | Medicament for treating coronary disease, angina pectoris and reducing blood fat, blood sugar, and preparation method thereof | |
| CN104095868B (en) | A kind of pharmaceutical composition and pharmaceutical applications thereof improving sugar tolerance | |
| CN102274285A (en) | Pharmaceutical composition for treating type 2 diabetes and complications thereof | |
| CN104127545B (en) | New application of murraya tetramera huang and extract thereof in preparation of medicines | |
| CN107349192A (en) | Poria cocos skin zone extract, Poria cocos eo-acid A and Poria cocos eo-acid B are in the purposes of regulation blood glucose | |
| CN102641312A (en) | Use of polyphenols from pomegranate flowers in preparation of medicaments for treating non-alcoholic fatty liver | |
| CN112675186B (en) | Pharmaceutical composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 |